Drug intelligence / Profile preview

RG001

Development stage: Unknown
Lead developer: Raygene
Modality: Small Molecules

Overview

RG001 (TATE) is a proprietary anti-tumor **small molecule** prodrug licensed by Ruizhen Pharmaceutical from abroad, designed for hypoxic tumor environments. It activates under low-oxygen conditions within tumors, converting to cytotoxic metabolites that selectively kill cancer cells. RG001 demonstrates synergistic effects with immune checkpoint inhibitors, enhancing anti-tumor activity, and is under joint clinical development with Alphamab Oncology's KN046 (PD-L1/CTLA-4 bispecific antibody) for post-line treatment of advanced hepatocellular carcinoma (HCC) and colorectal cancer (CRC) with liver metastasis.[3]

Other names: TATE

Beyond the preview

Go deeper on RG001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RG001.

Explore the full profile